Christopher Klein
2019
In 2019, Christopher Klein earned a total compensation of $1.5M as General Counsel & Secretary at RVL Pharmaceuticals plc.
Compensation breakdown
| Non-Equity Incentive Plan | $285,360 |
|---|---|
| Salary | $414,539 |
| Stock Awards | $799,998 |
| Other | $11,200 |
| Total | $1,511,097 |
Klein received $800K in stock awards, accounting for 53% of the total pay in 2019.
Klein also received $285.4K in non-equity incentive plan, $414.5K in salary and $11.2K in other compensation.
Rankings
In 2019, Christopher Klein's compensation ranked 7,284th out of 13,971 executives tracked by ExecPay. In other words, Klein earned more than 47.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,284 out of 13,971 | 48th |
Division Manufacturing | 2,806 out of 5,701 | 51st |
Major group Chemicals And Allied Products | 1,046 out of 2,200 | 53rd |
Industry group Drugs | 890 out of 1,886 | 53rd |
Industry Pharmaceutical Preparations | 660 out of 1,398 | 53rd |
Source: SEC filing on April 20, 2020.
Klein's colleagues
We found three more compensation records of executives who worked with Christopher Klein at RVL Pharmaceuticals plc in 2019.
News
RVL Pharmaceuticals plc Former EVP, Research & Development Tina deVries' 2022 pay slips 19% to $561K
April 24, 2023
RVL Pharmaceuticals plc CEO Brian Markison's 2021 pay falls 63% to $1.4M
April 25, 2022
RVL Pharmaceuticals plc CEO Brian Markison's 2020 pay slips 12% to $3.8M
April 26, 2021
RVL Pharmaceuticals plc CEO Brian Markison's 2019 pay jumps 291% to $4.3M
April 20, 2020